FilingReader Intelligence
Beryl Drugs approves unaudited financial results for quarter ended
March 4, 2025 at 05:00 AM UTC•By FilingReader AI
Beryl Drugs Limited (BSE:BERLDRG) announced its unaudited standalone financial results for the quarter ended December 31, 2024, showing a revenue from operations of ₹530.93 lacs and total income of ₹540.27 lacs. Expenses totaled ₹524.22 lacs, resulting in a profit before tax of ₹16.05 lacs. Net profit after tax stood at ₹5.22 lacs. Earnings per share were reported as ₹0.10.
This report was generated by FilingReader's AI system from regulatory filings and company disclosures. To request a correction, contact editorial@filingreader.com
Primary Source Document
BSE:BERLDRG•Bombay Stock Exchange
News Alerts
Get instant email alerts when Beryl Drugs publishes news
Free account required • Unsubscribe anytime